William Quinn
Directeur Général chez BOLT BIOTHERAPEUTICS, INC.
Fortune : 27 204 $ au 30/06/2024
Profil
William P.
Quinn founded Bullet Biotechnology, Inc. in 2011, where he worked as President, Chief Executive Officer & Director from 2011 to 2017.
Mr. Quinn also currently works at Bolt Biotherapeutics, Inc., as President, Chief Executive Officer, CFO & Director from 2024, Neurogastrx, Inc., as Director, Solar Roof Dynamics LLC, as Director from 2017, and A Foundation Building Strength For Nemaline Myopathy, as Director from 2011.
Mr. Quinn also formerly worked at Midnight Pharmaceuticals, Inc., as Director from 2013 to 2019, Jazz Pharmaceuticals, Inc., as Head-Corporate Development from 2003 to 2011, Sunesis Pharmaceuticals, Inc., as CFO, Senior VP-Finance & Corporate Development, and Novation Biosciences, Inc., as Chief Financial & Operating Officer from 2001 to 2002.
Mr. Quinn received his undergraduate degree and graduate degree from Stanford University and Masters Business Admin degree from Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/03/2024 | 36 272 ( 0,10% ) | 27 204 $ | 30/06/2024 |
Postes actifs de William Quinn
| Sociétés | Poste | Début |
|---|---|---|
| BOLT BIOTHERAPEUTICS, INC. | Directeur Général | 15/05/2024 |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Directeur/Membre du Conseil | - |
| Solar Roof Dynamics LLC | Directeur/Membre du Conseil | 01/11/2017 |
| A Foundation Building Strength For Nemaline Myopathy | Directeur/Membre du Conseil | 01/03/2011 |
Anciens postes connus de William Quinn
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur Financier/CFO | 01/05/2020 |
Midnight Pharmaceuticals, Inc.
 Midnight Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midnight Pharmaceuticals, Inc. develops novel products for the treatment of insomnia. The CEO of the American company is Jed Black. | Directeur/Membre du Conseil | 01/02/2019 |
Bullet Biotechnology, Inc.
 Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Fondateur | 01/11/2017 |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01/06/2011 |
| Novation Biosciences, Inc. | Directeur Financier/CFO | 01/12/2002 |
Formation de William Quinn
| Stanford University | Graduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BOLT BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Health Technology |
| Novation Biosciences, Inc. | |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
| Solar Roof Dynamics LLC | |
Midnight Pharmaceuticals, Inc.
Midnight Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midnight Pharmaceuticals, Inc. develops novel products for the treatment of insomnia. The CEO of the American company is Jed Black. | Health Technology |
| A Foundation Building Strength For Nemaline Myopathy |
